RARE Relative Valuation
RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RARE is overvalued; if below, it's undervalued.
Historical Valuation
Ultragenyx Pharmaceutical Inc (RARE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.44. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：36.45
Fair
-7.39
PE
1Y
3Y
5Y
Trailing
Forward
-10.10
EV/EBITDA
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBITDA of -10.10. The 5-year average EV/EBITDA is -9.94. The thresholds are as follows: Strongly Undervalued below -22.02, Undervalued between -22.02 and -15.98, Fairly Valued between -3.90 and -15.98, Overvalued between -3.90 and 2.14, and Strongly Overvalued above 2.14. The current Forward EV/EBITDA of -10.10 falls within the Historic Trend Line -Fairly Valued range.
-8.48
EV/EBIT
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBIT of -8.48. The 5-year average EV/EBIT is -9.56. The thresholds are as follows: Strongly Undervalued below -20.42, Undervalued between -20.42 and -14.99, Fairly Valued between -4.13 and -14.99, Overvalued between -4.13 and 1.30, and Strongly Overvalued above 1.30. The current Forward EV/EBIT of -8.48 falls within the Historic Trend Line -Fairly Valued range.
4.70
PS
Ultragenyx Pharmaceutical Inc. (RARE) has a current PS of 4.70. The 5-year average PS is 10.18. The thresholds are as follows: Strongly Undervalued below -2.67, Undervalued between -2.67 and 3.76, Fairly Valued between 16.60 and 3.76, Overvalued between 16.60 and 23.02, and Strongly Overvalued above 23.02. The current Forward PS of 4.70 falls within the Historic Trend Line -Fairly Valued range.
-9.39
P/OCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/OCF of -9.39. The 5-year average P/OCF is -3.66. The thresholds are as follows: Strongly Undervalued below -85.13, Undervalued between -85.13 and -44.39, Fairly Valued between 37.07 and -44.39, Overvalued between 37.07 and 77.81, and Strongly Overvalued above 77.81. The current Forward P/OCF of -9.39 falls within the Historic Trend Line -Fairly Valued range.
364.71
P/FCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/FCF of 364.71. The 5-year average P/FCF is -26.18. The thresholds are as follows: Strongly Undervalued below -595.70, Undervalued between -595.70 and -310.94, Fairly Valued between 258.58 and -310.94, Overvalued between 258.58 and 543.33, and Strongly Overvalued above 543.33. The current Forward P/FCF of 364.71 falls within the Overvalued range.
Ultragenyx Pharmaceutical Inc (RARE) has a current Price-to-Book (P/B) ratio of 383.12. Compared to its 3-year average P/B ratio of 42.75 , the current P/B ratio is approximately 796.16% higher. Relative to its 5-year average P/B ratio of 28.06, the current P/B ratio is about 1265.53% higher. Ultragenyx Pharmaceutical Inc (RARE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.29%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.66% , the current FCF yield is about -100.00% lower.
384.07
P/B
Median3y
42.75
Median5y
28.06
-12.86
FCF Yield
Median3y
-14.29
Median5y
-11.66
Competitors Valuation Multiple
The average P/S ratio for RARE's competitors is 0.00, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 14.65%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RARE decreased by 13.14% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -95.71 to -112.81.
The secondary factor is the Revenue Growth, contributed 14.65%to the performance.
Overall, the performance of RARE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Ultragenyx Pharmaceutical Inc (RARE) currently overvalued or undervalued?
What is Ultragenyx Pharmaceutical Inc (RARE) fair value?
How does RARE's valuation metrics compare to the industry average?
What is the current P/B ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Dec 05 2025?
What is the current FCF Yield for Ultragenyx Pharmaceutical Inc (RARE) as of Dec 05 2025?
What is the current Forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Dec 05 2025?